Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16765747 | 1.00 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2GPR119CHRM2 | |
| SCHEMBL21850259 | 1.00 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2GPR119CHRM2 | |
| SCHEMBL19940553 | 1.00 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2GPR119CHRM2 | |
| SCHEMBL9932878 | 1.00 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2GPR119CHRM2 | |
| SCHEMBL19408782 | 0.86 | PPM1D (0.31) | — | |
| SCHEMBL1443674 | 0.86 | PPM1D (0.31) | — | |
| SCHEMBL28896871 | 0.86 | PPM1D (0.31) | — | |
| SCHEMBL16764759 | 0.84 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2GPR119CHRM2 | |
| SCHEMBL20599050 | 0.84 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2GPR119CHRM2 | |
| SCHEMBL20599053 | 0.84 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2GPR119CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | PFIZER INC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-07-25 | — | — | US | disclosed |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3318565-B1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3461824-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Biogen MA Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20170247372-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-9617258-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-29 | — | — | US | disclosed |
| EP-3077395-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | Pfizer Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9249146-B2 | Bruton'S tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150158864-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. | 2015-06-11 | — | — | US | disclosed |
| WO-2015083028-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-10-16 | — | — | US | disclosed |
| US-8785440-B2 | Bruton's tyrosine kinase inhibitors | BIOGEN IDEC MA, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | NR1H2 4428/4885USP2 2007/4885SMN1; SMN2 4292/4885 |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | NR1H2 4428/4885USP2 2007/4885SMN1; SMN2 4292/4885 |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | NR1H2 4428/4885USP2 2007/4885SMN1; SMN2 4292/4885 |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | ACR, PKD2, PGA5 | NR1H2 4687/4885USP2 2584/4885SMN1; SMN2 4491/4885 |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | NR1H2 4428/4885USP2 2007/4885SMN1; SMN2 4292/4885 |
| US-20170247372-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | NR1H2 4841/4885USP2 796/4885SMN1; SMN2 4248/4885 |
| US-20150158864-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | NR1H2 4598/4885USP2 1008/4885SMN1; SMN2 3579/4885 |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | JAK2, JAK3, JAK1 | NR1H2 4870/4885USP2 1262/4885SMN1; SMN2 3368/4885 |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | JAK2, JAK3, JAK1 | NR1H2 4786/4885USP2 1029/4885SMN1; SMN2 3909/4885 |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | NR1H2 4428/4885USP2 2007/4885SMN1; SMN2 4292/4885 |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | NR1H2 4841/4885USP2 796/4885SMN1; SMN2 4248/4885 |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | NR1H2 4428/4885USP2 2007/4885SMN1; SMN2 4292/4885 |
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | NR1H2 4428/4885USP2 2007/4885SMN1; SMN2 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.